At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback